10 20 30 40 50 60 70 80 2G0G - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER TRANSCRIPTION ACTIVATOR 13-FEB-06 2G0G
TITLE STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR TITLE 2 PARTIAL AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHY TITLE 3 AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN(RESIDUES 207-477); COMPND 5 SYNONYM: PPAR-GAMMA; COMPND 6 ENGINEERED: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PGEX6P-1
KEYWDS PPAR, TRANSCRIPTION ACTIVATOR
EXPDTA X-RAY DIFFRACTION
AUTHOR I.L.LU,Y.H.PENG,C.F.HUANG,Y.T.LIN,J.T.A.HSU,S.Y.WU
REVDAT 2 24-FEB-09 2G0G 1 VERSN REVDAT 1 16-MAY-06 2G0G 0
JRNL AUTH I.L.LU,C.F.HUANG,Y.H.PENG,Y.T.LIN,H.P.HSIEH, JRNL AUTH 2 C.T.CHEN,T.W.LIEN,H.J.LEE,N.MAHINDROO,E.PRAKASH, JRNL AUTH 3 A.YUEH,H.Y.CHEN,C.M.GOPARAJU,X.CHEN,C.C.LIAO, JRNL AUTH 4 Y.S.CHAO,J.T.HSU,S.Y.WU JRNL TITL STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF JRNL TITL 2 PPARGAMMA PARTIAL AGONISTS: VIRTUAL SCREENING, JRNL TITL 3 X-RAY CRYSTALLOGRAPHY, AND IN VITRO/IN VIVO JRNL TITL 4 BIOLOGICAL ACTIVITIES JRNL REF J.MED.CHEM. V. 49 2703 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16640330 JRNL DOI 10.1021/JM051129S
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. 2.54 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.54 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 3.722 REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 17885 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.216 REMARK 3 R VALUE (WORKING SET) : 0.216 REMARK 3 FREE R VALUE : 0.264 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 975 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 REFLECTION IN BIN (WORKING SET) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE SET COUNT : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4354 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 28 REMARK 3 SOLVENT ATOMS : 90 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): NULL REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): NULL REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): NULL REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : NULL REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): NULL ; 0.008 ; NULL REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): NULL ; 1.978 ; NULL REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): NULL ; NULL ; NULL REMARK 3 GENERAL PLANES REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : NULL REMARK 3 ION PROBE RADIUS : NULL REMARK 3 SHRINKAGE RADIUS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 2G0G COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 16-FEB-06. REMARK 100 THE RCSB ID CODE IS RCSB036532.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-MAR-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSRRC REMARK 200 BEAMLINE : BL17B2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : MONOCHROMATOR REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17885 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.540 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.54 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.61 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.7 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 2ATH REMARK 200 REMARK 200 REMARK: NULL
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.73 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.35 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% PEG3350, PH 8.0, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 291K
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 44.40250 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE SECOND PART OF THE BIOLOGICAL ASSEMBLY IS GENERATED REMARK 300 BY THE TWO FOLD AXIS: REMARK 300 -X, Y+1/2, -Z;
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LYS A 404 CD - CE - NZ ANGL. DEV. = 13.9 DEGREES REMARK 500 GLU B 207 OE1 - CD - OE2 ANGL. DEV. = 7.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 29.78 -61.66 REMARK 500 ASP A 243 58.39 -173.86 REMARK 500 LYS A 244 129.98 55.59 REMARK 500 ASP A 260 0.34 -58.34 REMARK 500 LYS A 261 2.97 -66.41 REMARK 500 ILE A 262 92.70 -67.35 REMARK 500 LYS A 263 -40.68 -144.16 REMARK 500 PRO A 269 96.17 -37.23 REMARK 500 LEU A 270 -169.18 -175.85 REMARK 500 GLU A 272 -136.43 -94.57 REMARK 500 GLN A 273 86.03 -65.56 REMARK 500 ASP A 310 142.87 -39.67 REMARK 500 LYS A 358 -70.28 -7.98 REMARK 500 THR A 461 -144.86 -91.18 REMARK 500 MET A 463 -83.91 -128.66 REMARK 500 SER A 464 124.46 64.26 REMARK 500 ASP A 475 21.49 36.92 REMARK 500 THR B 238 -107.55 -88.72 REMARK 500 THR B 241 66.55 33.14 REMARK 500 ASP B 243 -58.09 -160.24 REMARK 500 LYS B 244 35.91 -74.77 REMARK 500 ASP B 251 -169.88 -162.48 REMARK 500 ASP B 260 48.68 -104.66 REMARK 500 LYS B 261 6.58 -159.21 REMARK 500 ILE B 262 18.28 -141.87 REMARK 500 LYS B 263 -28.15 -157.76 REMARK 500 LYS B 265 -80.64 -53.07 REMARK 500 ILE B 267 34.53 21.18 REMARK 500 PRO B 269 -155.26 -101.22 REMARK 500 GLN B 271 147.11 172.39 REMARK 500 GLU B 272 -164.12 -70.13 REMARK 500 GLN B 273 -140.28 -107.07 REMARK 500 ASN B 335 -169.73 -120.75 REMARK 500 SER B 342 74.46 46.14 REMARK 500 GLU B 343 42.32 37.68 REMARK 500 LYS B 358 -60.56 -16.93 REMARK 500 LEU B 393 50.70 -94.58 REMARK 500 HIS B 425 55.93 -143.75 REMARK 500 SER B 464 71.72 169.32 REMARK 500 REMARK 500 REMARK: NULL
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SP0 A 101
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2G0H RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH DIFFERENT LIGAND
DBREF 2G0G A 207 477 UNP P37231 PPARG_HUMAN 235 505 DBREF 2G0G B 207 477 UNP P37231 PPARG_HUMAN 235 505
SEQRES 1 A 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 A 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 A 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 A 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 A 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 A 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 A 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 A 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 A 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 A 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 A 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 A 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 A 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 A 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 A 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 A 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 A 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 A 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 A 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 A 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 A 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR SEQRES 1 B 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 B 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 B 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 B 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 B 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 B 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 B 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 B 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 B 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 B 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 B 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 B 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 B 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 B 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 B 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 B 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 B 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 B 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 B 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 B 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 B 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR
HET SP0 A 101 28
HETNAM SP0 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H- HETNAM 2 SP0 PYRAZOL-5-YL]BENZENESULFONAMIDE
FORMUL 3 SP0 C19 H13 F2 N3 O2 S2 FORMUL 4 HOH *90(H2 O)
HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 ASP A 260 1 10 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 ASP A 310 SER A 332 1 23 HELIX 6 6 ARG A 350 SER A 355 1 6 HELIX 7 7 PRO A 359 PHE A 363 5 5 HELIX 8 8 MET A 364 LEU A 377 1 14 HELIX 9 9 ASP A 380 LEU A 393 1 14 HELIX 10 10 ASN A 402 HIS A 425 1 24 HELIX 11 11 GLN A 430 GLU A 460 1 31 HELIX 12 12 HIS A 466 LYS A 474 1 9 HELIX 13 13 GLU B 207 PHE B 226 1 20 HELIX 14 14 THR B 229 THR B 238 1 10 HELIX 15 15 ASP B 251 ASP B 260 1 10 HELIX 16 16 GLU B 276 SER B 302 1 27 HELIX 17 17 ASP B 310 ALA B 331 1 22 HELIX 18 18 ARG B 350 SER B 355 1 6 HELIX 19 19 ARG B 357 ASP B 362 1 6 HELIX 20 20 MET B 364 ALA B 376 1 13 HELIX 21 21 ASP B 380 LEU B 393 1 14 HELIX 22 22 ASN B 402 HIS B 425 1 24 HELIX 23 23 GLN B 430 GLU B 460 1 31 HELIX 24 24 LEU B 468 TYR B 473 1 6
SHEET 1 A 3 PHE A 247 ILE A 249 0 SHEET 2 A 3 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 3 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338
SITE 1 AC1 11 PHE A 282 CYS A 285 GLN A 286 SER A 289 SITE 2 AC1 11 TYR A 327 PHE A 363 LYS A 367 HIS A 449 SITE 3 AC1 11 LEU A 465 LEU A 469 TYR A 473
CRYST1 56.419 88.805 58.258 90.00 89.99 90.00 P 1 21 1 4
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.017725 0.000000 -0.000005 0.00000
SCALE2 0.000000 0.011261 0.000000 0.00000
SCALE3 0.000000 0.000000 0.017165 0.00000